ABSTRACT

Objective: Tetrahydroisoquinoline alkaloid derivative is a nicotinic neurotransmitter receptor antagonist [1] that has been isolated from a spread of plant sources together with sacred lotus.Dimerization results in the biscoclaurine alkaloids like cepharanthine and many other phytoconstituents like quercetin, Luteolin, kaempferol etc. [2]., Coclaurine mechanism of action states that, Coclaurine N?methyltransferase (CNMT) is a key enzyme in the pathway to (S)?reticulene, installing the N?methyl substituent that is essential for the bioactivity of many BIAs (Benzylisoquinoline Alkaloids) [3]. From the literature review we have been examined that there are no recent studieson regards with treatment for COVID 19 with the tetrahydroisoquinoline alkaloid from sacred lotus. METHODOLOGY: The aim of the study was to investigate the binding efficiency of selected currently COVID 19 treatingsynthetic drugs, and compared with the plant constituents. The target selected for the study were extracted from Protein Data Bank, and the ligands were extracted from Pubchem. The compounds were screened and shown great binding energy. Keywords: Tetrahydroisoquinoline, Alkaloid Derivative, COVID 19, Insilico studies
Publication date: 01/07/2022

https://ijbpas.com/pdf/2022/July/MS_IJBPAS_2022_6247.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2022/11.7.6247